0000012239
false
0000012239
2022-06-28
2022-06-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): June
28, 2022
| AIKIDO PHARMA INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware |
|
000-05576 |
|
52-0849320 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
One
Rockefeller Plaza, 11th
Floor
New York, NY |
|
10020 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (703) 992-9325
| Not Applicable |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
AIKI |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
As previously disclosed, on August
10, 2021, Aikido Pharma Inc. (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”)
informing the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business
days as required by Nasdaq Listing Rule 5550(a)(2).
On June 23, 2022, the Company
received a letter from Nasdaq informing the Company that it had regained compliance with Nasdaq Listing Rule 5550(a)(2) because for the
last 11 consecutive business days, from June 7 through June 22, 2022, the closing bid price of the Company’s common stock had been
at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers
this matter closed.
On June 28, 2022 the Company issued
a press release announcing it regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers this matter closed. A copy
of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: June 28, 2022 |
AIKIDO PHARMA INC. |
| |
|
| |
By: |
/s/ Anthony Hayes |
| |
Name: |
Anthony Hayes |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
AIkido Pharma Inc. Regains Compliance with NASDAQ
Listing Requirements
NEW YORK, NY
June 28, 2022 /PRNewswire/ AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced
that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating
that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under
Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ's requirements when the closing bid price for the Company's common
stock was at or above $1.00 for 10 consecutive business days and the matter is now closed.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially
formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's
platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing
an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University
of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic
cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this
press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,”
“might,” “will,” “should,” “believe,” “expect,” “anticipate,”
“estimate,” “continue,” “predict,” “forecast,” “project,” “plan,”
“intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon
current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in
the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could
be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information,
future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com